EDN-OL1 reduces amyloid in the brain
Please Help Support Alzheimer's Research Today!
Your Alzheimer's donation will help billions live without it. Donate online now
Edunn's lead drug candidate, EDN-OL1, is an oligonucleotide-based drug that has shown promise in halting and reversing the progression of AD in animal models. EDN-OLI reduces the production of amyloid beta proteins found in the brain and believed to cause AD.
"The grant will support research to further confirm that EDN-OL1 reduces amyloid in the brain," said Thomas Darling, PhD, Edunn's President and CEO. "These data will be included in submissions to FDA and regulatory agencies as we continue the preclinical development of EDN-OL1 for the treatment and prevention of Alzheimer's disease and Down syndrome."
"Edunn has data to demonstrate that EDN-OL1 restores learning and memory in animal models and has an excellent safety record," said Howard Fillit, MD, ADDF's Executive Director. "If the current studies are successful, they will accelerate this compound into human clinical trials."...http://www.medicalnewstoday.com
Posted YVN
Слушать Радио Радио СтолицаYour Alzheimer's donation will help billions live without it. Donate online now
The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it is providing a grant of $100,000 to Edunn Biotechnology, Inc. (an early stage drug development company with an exclusive license to a novel class of oligonucleotides proven to cross the blood-brain barrier. This new class of central nervous system (CNS) drugs shows promise in treating Alzheimer's disease, Down syndrome, stroke and traumatic brain injury. Edunn's business model is to encourage partnering and investment discussions as EDN-OL1 goes through animal safety and initial primate studies early in development on the route leading to Phase 1 clinical trials. Management believes the company can spin out other CNS drug candidates from this platform.), an early stage company dedicated to developing a novel class of drugs to treat and prevent Alzheimer's disease (AD).
Edunn's lead drug candidate, EDN-OL1, is an oligonucleotide-based drug that has shown promise in halting and reversing the progression of AD in animal models. EDN-OLI reduces the production of amyloid beta proteins found in the brain and believed to cause AD.
"The grant will support research to further confirm that EDN-OL1 reduces amyloid in the brain," said Thomas Darling, PhD, Edunn's President and CEO. "These data will be included in submissions to FDA and regulatory agencies as we continue the preclinical development of EDN-OL1 for the treatment and prevention of Alzheimer's disease and Down syndrome."
"Edunn has data to demonstrate that EDN-OL1 restores learning and memory in animal models and has an excellent safety record," said Howard Fillit, MD, ADDF's Executive Director. "If the current studies are successful, they will accelerate this compound into human clinical trials."...http://www.medicalnewstoday.com
Synbiotic may improve gut, immune health in elderly
Consumption of a combination probiotic and prebiotic supplement for two weeks was found to improve the gut and immune health of a group of seniors, according to a study conducted by Danisco. ...http://www.nutraingredients.com
posted by Valery Yermalitsky at
6:46 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home